Publicaciones (46) Publicaciones de EDUARDO VILLACORTA ARGÜELLES

2024

  1. Characterization of the plasma proteomic profile of Fabry disease: Potential sex- and clinical phenotype-specific biomarkers

    Translational Research, Vol. 269, pp. 47-63

  2. Intermediate-effect size p.Arg637Gln in FHOD3 increases risk of HCM and is associated with an aggressive phenotype in homozygous carriers

    Journal of Medical Genetics, Vol. 61, Núm. 5, pp. 423-427

  3. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

    Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651

  4. Variable Penetrance and Expressivity of a Rare Pore Loss-of-Function Mutation (p.L889V) of Nav1.5 Channels in Three Spanish Families

    International Journal of Molecular Sciences, Vol. 25, Núm. 9

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  2. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study

    Frontiers in Cardiovascular Medicine, Vol. 10

  3. Heart failure in a patient with multiple myeloma

    REC: CardioClinics, Vol. 58, Núm. 4, pp. 333-334

  4. Importance of genetic study in elderly patients with transthyretin cardiac amyloidosis

    Medicina Clinica, Vol. 161, Núm. 9, pp. 382-385

  5. Late gadolinium enhancement distribution patterns in non-ischaemic dilated cardiomyopathy: genotype-phenotype correlation

    European heart journal. Cardiovascular Imaging, Vol. 25, Núm. 1, pp. 75-85

  6. Selection of the best of 2022 in familial heart disease and cardiovascular genetics

    REC: CardioClinics, Vol. 58, pp. S68-S73

  7. Unravelling an hypertrophic myocardiopathy

    European heart journal, Vol. 44, Núm. 29, pp. 2788

2022

  1. Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy

    European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1183-1196

  2. Drug-eluting stents and contemporary dual antiplatelet therapy in revascularized STEMI. The times they are a-changin’?

    Revista Espanola de Cardiologia, Vol. 75, Núm. 8, pp. 623-625

  3. Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198

  4. Natural History of MYH7-Related Dilated Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 80, Núm. 15, pp. 1447-1461

  5. Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers

    Revista Espanola de Cardiologia, Vol. 75, Núm. 9, pp. 735-747

  6. Selection of the best of 2021 in familial heart disease and cardiovascular genetics

    REC: CardioClinics, Vol. 57, pp. S54-S59

2021

  1. A rare HCN4 variant with combined sinus bradycardia, left atrial dilatation, and hypertrabeculation/left ventricular noncompaction phenotype

    Revista Espanola de Cardiologia, Vol. 74, Núm. 9, pp. 781-789

  2. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy

    European Heart Journal, Vol. 42, Núm. 32, pp. 3063-3073

  3. Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 78, Núm. 17, pp. 1682-1699